Pomalidomide-d5

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H361：生殖能または胎児への悪影響のおそれの疑い

• 注意書き

  P201：使用前に取扱説明書を入手すること。

  P202：全ての安全注意を読み理解するまで取り扱わないこ と。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P308+P313：暴露または暴露の懸念がある場合：医師の診断/手当てを 受けること。

  P405：施錠して保管すること。

  P501：内容物/容器を．．．に廃棄すること。

Pomalidomide-d5 化学特性,用途語,生産方法

• 説明

  Pomalidomide-d₅ is intended for use as an internal standard for the quantification of pomalidomide by GC- or LC-MS. Pomalidomide is an analog of thalidomide that inhibits the E3 ligase protein cereblon (CRBN) with an IC₅₀ value of approximately 3 μM for the human recombinant CRBN-DNA damage binding protein-1 (CRBN-DDB1) complex. It inhibits autoubiquitination of CRBN in HEK293T cells expressing CRBN but not those expressing a thalidomide-binding defective CRBN mutation. It inhibits proliferation of U266 myeloma cells when used at concentrations ranging from 0.1 to 10 μM. Pomalidomide also has antiangiogenic and immunomodulatory effects against myeloma cells, modulating cell adhesion, decreasing production of key pro-survival cytokines, including TNF-α, and triggering the activation of caspase-8. Pomalidomide (3 mg/kg per day), in combination with dexamethasone, reduces tumor growth in a H929 R10-1 lenalidomide-resistant mouse xenograft model. Formulations containing pomalidomide have been used in the treatment of multiple myeloma.

• 使用

  Pomalidomide-d5 is the labeled analogue of Pomalidomide (P688200), a thalidomide derivative, a potent inhibitor of TNF-α production. It is an antiinflammatory and antitumor agent used in the treatment of multiple myeloma.

Pomalidomide-d5 生産企業

Global(9)Suppliers

1377838-49-7, Pomalidomide-d5 キーワード